Maxim Group’s healthcare analyst Jason Kolbert weighed in today with research reports on the Canadian urology company Sophiris Bio Inc (NASDAQ:SPHS), Israeli stem cell company Pluristem Therapeutics Inc. (NASDAQ:PSTI), …
In a research report issued today, Maxim Group analyst Jason Kolbert assigned a Buy rating on Advanced Cell Technology (ACTC) with a price target …
Tekmira Pharmaceuticals (NASDAQ: TKMR) is a Vancouver, Canada based bio-pharmaceutical company who is a known world leader in RNA Interference (RNAi) delivery technology. The …
In a research note issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharmaceuticals (TKMR) with a $23 price target, following a report that created a buzz around Ebola drug …
Inovio Pharmaceuticals (INO) announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia …
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a Buy rating on IsoRay, Inc. (ISR) and increased his price target to $5.
In a research report issued today, IntelliPharmaCeutics International Inc. (IPCI) was downgraded by analyst Jason Kolbert at Maxim Group from Buy to Hold.
Maxim maintains a Buy rating and $7.00 price target on Cesca Therapeutics Inc.
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a “Buy” rating on StemCells Inc. (STEM), and a price target of $2.
In a report published today, Maxim analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals, Inc. (INO) with an adjusted price target of $18.
